Clinical features and prognosis of 118 children with histiocytic necrotizing lymphadenitis

Objective: To explore the clinical features and prognosis of children with histiocytic necrotizing lymphadenitis (HNL). Methods: The clinical data of 118 children with HNL diagnosed and treated in the Department of Rheumatology and Immunology of Children's Hospital, Capital Institute of Pediatr...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 61(2023), 6 vom: 02. Juni, Seite 533-537
1. Verfasser: Zhang, D (VerfasserIn)
Weitere Verfasser: Su, G X, Wu, F Q, Zhu, J, Kang, M, Xu, Y J, Li, M, Lai, J M
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Antibodies, Antinuclear Steroids
LEADER 01000caa a22002652c 4500
001 NLM358141192
003 DE-627
005 20250304215447.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20230110-00020  |2 doi 
028 5 2 |a pubmed25n1193.xml 
035 |a (DE-627)NLM358141192 
035 |a (NLM)37312465 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Zhang, D  |e verfasserin  |4 aut 
245 1 0 |a Clinical features and prognosis of 118 children with histiocytic necrotizing lymphadenitis 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 15.06.2023 
500 |a Date Revised 15.06.2023 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To explore the clinical features and prognosis of children with histiocytic necrotizing lymphadenitis (HNL). Methods: The clinical data of 118 children with HNL diagnosed and treated in the Department of Rheumatology and Immunology of Children's Hospital, Capital Institute of Pediatrics from January 2014 to December 2021 were retrospectively analyzed. The clinical symptoms, laboratory examination, imaging examination, pathological findings, treatment and follow-up were analyzed. Results: Among the 118 patients, 69 were males and 49 were females. The age of onset was 10.0 (8.0, 12.0) years, ranging from 1.5 to 16.0 years. All the children had fever lymph node enlargement, blood system involvement in 74 cases (62.7%), skin injury in 39 cases (33.1%). The main manifestations of laboratory examination were increased erythrocyte sedimentation rate in 90 cases (76.3%), decreased hemoglobin in 58 cases (49.2%), decreased white blood cells in 54 cases (45.8%) and positive antinuclear antibody in 35 cases (29.7%). Ninety-seven cases (82.2%) underwent B-mode ultrasound of lymph nodes, showing nodular lesions with low echo in the neck; 22 cases (18.6%) underwent cervical X-ray and (or) CT; 7 cases (5.9%) underwent cervical magnetic resonance imaging. Lymph node biopsy was performed in all 118 cases, and the pathological results did not support malignant diseases such as lymphoma or Epstein-Barr virus infection, suggesting HNL. Fifty-seven cases (48.3%) recovered without treatment, 61 cases (51.7%) received oral steroid therapy, and 4 cases (3.4%) received indomethacin as anal stopper. The 118 cases were followed up for 4 (2, 6) years, ranging from 1 to 7 years, 87 cases (73.7%) had one onset and did not develop into other rheumatological diseases, and 24 cases (20.3%) had different degrees of recurrence, 7 cases (5.9%) had multiple system injuries, and all of the tested autoantibodies were positive for medium and high titers. All of them developed into other rheumatic immune diseases, among which 5 cases developed into systemic lupus erythematosus and 2 cases developed into Sjogren's syndrome; 7 cases were given oral steroid therapy, including 6 cases plus immunosuppressant and 2 cases receiving methylprednisolone 20 mg/kg shock therapy. Conclusions: The first-onset HNL portion is self-healing, hormone-sensitive and has a good prognosis. For HNL with repeated disease and multiple system injury, antinuclear antibody titer should be monitored during follow-up, and attention should be paid to the possibility of developing into other rheumatological diseases, with poor prognosis 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Antibodies, Antinuclear  |2 NLM 
650 7 |a Steroids  |2 NLM 
700 1 |a Su, G X  |e verfasserin  |4 aut 
700 1 |a Wu, F Q  |e verfasserin  |4 aut 
700 1 |a Zhu, J  |e verfasserin  |4 aut 
700 1 |a Kang, M  |e verfasserin  |4 aut 
700 1 |a Xu, Y J  |e verfasserin  |4 aut 
700 1 |a Li, M  |e verfasserin  |4 aut 
700 1 |a Lai, J M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 61(2023), 6 vom: 02. Juni, Seite 533-537  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnas 
773 1 8 |g volume:61  |g year:2023  |g number:6  |g day:02  |g month:06  |g pages:533-537 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20230110-00020  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 61  |j 2023  |e 6  |b 02  |c 06  |h 533-537